Oracle has signed up to be a cornerstone investor for Oxford Nanopore’s initial public offering, putting up half of the $410m target.

Oxford Nanopore, the UK-based DNA sequencing technology spinout of University of Oxford, has secured software producer Oracle as a cornerstone investor for its initial public offering on the London Stock Exchange.
Oracle will invest £150m ($205m), halfway to Oxford Nanopore’s target of $410m.
The two companies have also entered into a partnership to explore potential applications for genomic sequencing running on Oracle’s cloud. They expect to tackle large-scale projects spanning drug discovery, healthcare, epidemiology and whole-genome sequencing.
…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in